Catalog No.
DHB95906
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Chimeric
Isotype
IgG1-lambda
Clonality
Monoclonal
Applications
Research Grade Biosimilar
Target
T-cell surface antigen T4/Leu-3, T-cell surface glycoprotein CD4, CD4
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P01730
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
IDEC CE9.1/SB-210396, CAS: 174722-30-6
Clone ID
Keliximab
Note
For research use only. Not suitable for clinical or therapeutic use.
Randomised, dose-ranging, placebo-controlled study of chimeric antibody to CD4 (keliximab) in chronic severe asthma., PMID:9798587
Intra-articular primatised anti-CD4: efficacy in resistant rheumatoid knees. A study of combined arthroscopy, magnetic resonance imaging, and histology., PMID:10340958
Flow cytometry in the preclinical development of biopharmaceuticals., PMID:10367670
Elimination of Fc receptor-dependent effector functions of a modified IgG4 monoclonal antibody to human CD4., PMID:10657642
Inhibition of contact sensitivity in human CD4+ transgenic mice by human CD4-specific monoclonal antibodies: CD4+ T-cell depletion is not required., PMID:10692049
Comparative pharmacodynamics of keliximab and clenoliximab in transgenic mice bearing human CD4., PMID:10734150
Preclinical development of keliximab, a Primatized anti-CD4 monoclonal antibody, in human CD4 transgenic mice: characterization of the model and safety studies., PMID:10918514
Immunomodulatory effects of anti-CD4 antibody in host resistance against infections and tumors in human CD4 transgenic mice., PMID:11160000
Modification of the Fc region of a primatized IgG antibody to human CD4 retains its ability to modulate CD4 receptors but does not deplete CD4(+) T cells in chimpanzees., PMID:11161972
The effects of an anti-CD4 monoclonal antibody, keliximab, on peripheral blood CD4+ T-cells in asthma., PMID:11510804
CD4 mAb induced apoptosis of peripheral T cells: multiparameter subpopulation analysis by flow cytometry using Attractors., PMID:11687240
CD4 coating, but not CD4 depletion, is a predictor of efficacy with primatized monoclonal anti-CD4 treatment of active rheumatoid arthritis., PMID:11838838
Practical aspects of including functional endpoints in developmental toxicity studies. Case study: immune function in HuCD4 transgenic mice exposed to anti-CD4 MAb in utero., PMID:12458908
Antibody-mediated stripping of CD4 from lymphocyte cell surface in patients with rheumatoid arthritis., PMID:12509613
Antibody therapy for rheumatoid arthritis., PMID:12810200
Biological agents in rheumatoid arthritis: which ones could be used in combination?, PMID:18020567
[Brain metastasis in breast cancer]., PMID:22238942
Intra-articular primatised anti-CD4: efficacy in resistant rheumatoid knees. A study of combined arthroscopy, magnetic resonance imaging, and histology, PMID: 10340958
Modification of the Fc region of a primatized IgG antibody to human CD4 retains its ability to modulate CD4 receptors but does not deplete CD4(+) T cells in chimpanzees, PMID: 11161972
[Brain metastasis in breast cancer], PMID: 22238942
Inhibition of contact sensitivity in human CD4+ transgenic mice by human CD4-specific monoclonal antibodies: CD4+ T-cell depletion is not required, PMID: 10692049
Biological agents in rheumatoid arthritis: which ones could be used in combination?, PMID: 18020567
Antibody-mediated stripping of CD4 from lymphocyte cell surface in patients with rheumatoid arthritis, PMID: 12509613
Practical aspects of including functional endpoints in developmental toxicity studies. Case study: immune function in HuCD4 transgenic mice exposed to anti-CD4 MAb in utero, PMID: 12458908
Elimination of Fc receptor-dependent effector functions of a modified IgG4 monoclonal antibody to human CD4, PMID: 10657642
CD4 mAb induced apoptosis of peripheral T cells: multiparameter subpopulation analysis by flow cytometry using Attractors, PMID: 11687240
Flow cytometry in the preclinical development of biopharmaceuticals, PMID: 10367670
Antibody therapy for rheumatoid arthritis, PMID: 12810200
Immunomodulatory effects of anti-CD4 antibody in host resistance against infections and tumors in human CD4 transgenic mice, PMID: 11160000
CD4 coating, but not CD4 depletion, is a predictor of efficacy with primatized monoclonal anti-CD4 treatment of active rheumatoid arthritis, PMID: 11838838
Preclinical development of keliximab, a Primatized anti-CD4 monoclonal antibody, in human CD4 transgenic mice: characterization of the model and safety studies, PMID: 10918514
Randomised, dose-ranging, placebo-controlled study of chimeric antibody to CD4 (keliximab) in chronic severe asthma, PMID: 9798587
Comparative pharmacodynamics of keliximab and clenoliximab in transgenic mice bearing human CD4, PMID: 10734150
The effects of an anti-CD4 monoclonal antibody, keliximab, on peripheral blood CD4+ T-cells in asthma, PMID: 11510804
For research use only. Not for human or drug use.
